Tacrolimus unguento

Translated title of the contribution: Tacrolimus ointment

Marzia Lazzerini, Federico Marchetti, Giorgio Longo

Research output: Contribution to journalArticlepeer-review

Abstract

The safety and efficacy of tacrolimus - a macrolide with immunosuppressive properties - were proven in atopic dermatitis in several trials versus placebo and in two trials versus topical steroids. The drug, as a 0.03% ointment, has been now approved for use in children older than two years affected by eczema, while the use of the 0.1% preparation, which has an activity comparable to medium strenght steroids, has been restricted to adults. The target of tacrolimus are T lymphocites and the receptors with high affinity for IgE on the Langerhans cells. Its cost is more than ten times higher than topical steroids and its use should therefore be limited to moderate to severe eczema resistant to conventional treatment with steroids.

Translated title of the contributionTacrolimus ointment
Original languageItalian
Pages (from-to)102-107
Number of pages6
JournalMedico e Bambino
Volume23
Issue number2
Publication statusPublished - Feb 29 2004

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Tacrolimus ointment'. Together they form a unique fingerprint.

Cite this